Leveraging early markers of cystic fibrosis structural lung disease to improve outcomes Source: Eur Respir J, 55 (4) 2000105; 10.1183/13993003.00105-2020 Year: 2020
Proteomic analysis of sputum from adults with cystic fibrosis and COPD: identification of potential biomarkers for disease monitoring Source: Eur Respir J 2006; 28: Suppl. 50, 152s Year: 2006
Elucidating progression of early cystic fibrosis lung disease Source: Eur Respir J, 50 (5) 1701916; 10.1183/13993003.01916-2017 Year: 2017
Identifying serum molecular biomarkers that distinguish emphysema and early fibrotic interstitial lung disease. Source: Virtual Congress 2021 – Biomarkers and e-health in idiopathic interstitial pneumonia Year: 2021
Early determinants of lung disease in children with cystic fibrosis Source: Virtual Congress 2020 – New frontiers in cystic fibrosis imaging and lung physiology Year: 2020
The use of non-invasive inflammatory markers to predict presence, severity and stability of cystic fibrosis lung disease Source: Eur Respir J 2006; 28: Suppl. 50, 327s Year: 2006
Novel imaging biomarkers for assessment of lung fibrosis and inflammation Source: Virtual Congress 2021 – Emerging imaging biomarkers in lung disease Year: 2021
Early cystic fibrosis lung disease Source: Eur Respir Monogr 2014; 64: 77-87 Year: 2014
Season dynamics of inflammatory markers in patients with cystic fibrosis lung disease Source: Eur Respir J 2002; 20: Suppl. 38, 528s Year: 2002
MMP-7 is a predictive biomarker of disease progression in patients with idiopathic pulmonary fibrosis Source: ERJ Open Res, 3 (1) 00074-2016; 10.1183/23120541.00074-2016 Year: 2017
Risk factors for lung disease progression in children with cystic fibrosis Source: Eur Respir J, 52 (4) 1801492; 10.1183/13993003.01492-2018 Year: 2018
Risk factors for lung disease progression in children with cystic fibrosis Source: Eur Respir J, 51 (6) 1702509; 10.1183/13993003.02509-2017 Year: 2018
Relations between the sinonasal development and the lung disease in cystic fibrosis patients Source: Eur Respir J 2005; 26: Suppl. 49, 103s Year: 2005
The cumulative effect of inflammation and infection on structural lung disease in early cystic fibrosis Source: Eur Respir J, 54 (1) 1801771; 10.1183/13993003.01771-2018 Year: 2019
Factors affecting progression of lung disease among patients with cystic fibrosis Source: International Congress 2019 – Physiology of cystic fibrosis Year: 2019
Predictive factors of lung function decline in adults with cystic fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 714s Year: 2006
The lung clearance index correlates with markers of pulmonary deterioration in patients with cystic fibrosis Source: Annual Congress 2013 –Cystic fibrosis: physiotherapy, exercise and lung function in adults and children Year: 2013
Progression of early CT-detected structural lung damage in cystic fibrosis Source: Annual Congress 2010 - Cystic fibrosis: new targets for therapy and impact of viral infections Year: 2010
Fibulin-1 is a novel biomarker of disease severity in pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013
Discovery and validation of peripheral blood gene expression profiles predictive of poor outcome and disease progression in idiopathic pulmonary fibrosis Source: International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis Year: 2014